We then analyzed transcriptomic data of pre-treatment breast cancer tumors in the I-SPY2 trial (Clark et al., 2021) to further explore metabolic gene alterations, in which HER2-positive breast cancer patients received trastuzumab plus paclitaxel, trastuzumab combined with pertuzumab, and paclitaxel or T-DM1 plus paclitaxel during neoadjuvant settings. Here, ERBB2 is linked to breast carcinoma.